The objective was to determine the impact of the coexpression of epidermal growth factor receptor (EGFR) and tumor marker c-erbB-2 on disease-free survival (DFS) and pelvic relapse-free survival (PRFS) in patients with locally advanced cervical cancer (LACC) receiving concurrent chemoradiotherapy.The expression of EGFR and c-erbB-2 was assessed by immunohistochemistry, which was centralized and blinded to outcome. Univariate and multivariate analyses were used to evaluate the impact of EGFR and c-erbB-2 on DFS and PRFS.170 patients with LACC were included and received concurrent chemoradiotherapy. 25 (15

作者：José, Pérez-Regadera；Alfonso, Sánchez-Mu?oz；Javier, De-la-Cruz；Claudio, Ballestín；David, Lora；Rosa, García-Martín；Cesar, Mendiola；Lorenzo, Alonso；Emilio, Alba；Eduardo, Lanzós

来源：Oncology 2009 年 76卷 2期